Fiduciary Trust Co. Has $9.55 Million Position in Gilead Sciences, Inc. (GILD)
Fiduciary Trust Co. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.6% during the third quarter, HoldingsChannel.com reports. The fund owned 117,811 shares of the biopharmaceutical company’s stock after selling 13,977 shares during the quarter. Fiduciary Trust Co.’s holdings in Gilead Sciences were worth $9,545,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in GILD. Sanders Capital LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at about $427,585,000. Renaissance Technologies LLC increased its position in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after acquiring an additional 2,700,600 shares during the period. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Gilead Sciences by 50.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after purchasing an additional 2,062,886 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $74.52 on Monday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market cap of $97,320.00, a PE ratio of 8.48, a P/E/G ratio of -1.58 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the firm posted $2.75 earnings per share. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.
A number of brokerages have recently weighed in on GILD. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Oppenheimer reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, December 21st. Finally, BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $85.03.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last three months. 1.30% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Fiduciary Trust Co. Has $9.55 Million Position in Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/fiduciary-trust-co-has-9-55-million-position-in-gilead-sciences-inc-gild/1798273.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.